Denali Therapeutics - DNLI Stock Forecast, Price & News

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wedbush lowered their price target on Denali Therapeutics from $62.00 to $48.00 in a research report on Friday, May 6th. The Goldman Sachs Group lowered their price target on Denali Therapeutics from $99.00 to $82.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. Finally, Berenberg Bank assumed coverage on Denali Therapeutics in a research report on Thursday, June 23rd. They set a "buy" rating and a $39.00 price target for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Denali Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $76.29.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI opened at $37.61 on Tuesday. Denali Therapeutics has a 52-week low of $20.24 and a 52-week high of $56.80. The firm has a market capitalization of $4.64 billion, a P/E ratio of -16.21 and a beta of 1.66. The stock has a 50 day moving average price of $31.68 and a 200-day moving average price of $30.39.

Denali Therapeutics (NASDAQ:DNLI - Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.07. Denali Therapeutics had a negative return on equity of 30.06% and a negative net margin of 252.50%. The firm had revenue of $52.50 million during the quarter, compared to analyst estimates of $44.66 million. During the same quarter in the prior year, the company earned ($0.50) EPS. The business's revenue was up 129.3% compared to the same quarter last year. On average, equities analysts forecast that Denali Therapeutics will post -2.65 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, Director Marc Tessier-Lavigne sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $35.61, for a total transaction of $712,200.00. Following the completion of the transaction, the director now owns 1,950,356 shares of the company's stock, valued at approximately $69,452,177.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 12.70% of the stock is owned by corporate insiders.